athenahealth, Inc (NASDAQ:ATHN) Director David Eric Robinson sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $133.94, for a total value of $669,700.00. Following the sale, the director now directly owns 8,596 shares of the company’s stock, valued at approximately $1,151,348.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of athenahealth, Inc (NASDAQ:ATHN) traded down $0.98 during trading on Friday, hitting $134.12. The stock had a trading volume of 70,323 shares, compared to its average volume of 250,242. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.67 and a quick ratio of 1.67. The firm has a market cap of $5,390.00, a PE ratio of 174.18, a price-to-earnings-growth ratio of 3.16 and a beta of 1.58. athenahealth, Inc has a fifty-two week low of $95.01 and a fifty-two week high of $158.66.
athenahealth (NASDAQ:ATHN) last posted its earnings results on Thursday, October 19th. The health services provider reported $0.56 EPS for the quarter, beating the consensus estimate of $0.50 by $0.06. athenahealth had a return on equity of 6.78% and a net margin of 2.65%. The firm had revenue of $304.60 million for the quarter, compared to analysts’ expectations of $310.52 million. During the same period last year, the firm earned $0.60 EPS. The firm’s revenue was up 10.1% compared to the same quarter last year. research analysts forecast that athenahealth, Inc will post 1.22 EPS for the current year.
A number of equities research analysts have issued reports on ATHN shares. Oppenheimer reissued a “buy” rating and set a $184.00 price target on shares of athenahealth in a research report on Friday, October 20th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $167.00 target price on shares of athenahealth in a research report on Tuesday, October 17th. KeyCorp reaffirmed a “buy” rating and issued a $170.00 target price on shares of athenahealth in a research report on Sunday, September 17th. SunTrust Banks reaffirmed a “buy” rating and issued a $156.00 target price on shares of athenahealth in a research report on Wednesday, October 25th. Finally, TheStreet downgraded athenahealth from a “b-” rating to a “c+” rating in a research report on Wednesday, October 11th. One analyst has rated the stock with a sell rating, seventeen have given a hold rating and nine have given a buy rating to the company. athenahealth currently has a consensus rating of “Hold” and a consensus price target of $143.43.
athenahealth Company Profile
athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.
Receive News & Ratings for athenahealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth and related companies with MarketBeat.com's FREE daily email newsletter.